tradingkey.logo

Penumbra Inc

PEN
查看詳細走勢圖
341.020USD
-1.170-0.34%
收盤 02/06, 16:00美東報價延遲15分鐘
13.35B總市值
80.66本益比TTM

Penumbra Inc

341.020
-1.170-0.34%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-0.34%

5天

-4.79%

1月

+7.87%

6月

+41.65%

今年開始到現在

+9.68%

1年

+30.82%

查看詳細走勢圖

TradingKey Penumbra Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Penumbra Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療設備與耗材行業排名30/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為357.05。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Penumbra Inc評分

相關信息

行業排名
30 / 205
全市場排名
116 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Penumbra Inc亮點

亮點風險
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
業績高增長
公司營業收入穩步增長,連續3年增長41.02%
估值低估
公司最新PE估值80.66,處於3年歷史低位
機構減倉
最新機構持股38.52M股,環比減少2.96%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉171.00股

分析師目標

基於 19 分析師
持有
評級
357.053
目標均價
+5.04%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Penumbra Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Penumbra Inc簡介

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
公司代碼PEN
公司Penumbra Inc
CEOElsesser (Adam)
網址https://www.penumbrainc.com/
KeyAI